Alexey Seregin

Dr. Alexey Seregin is the Vice President, Research and Development at Remedium Bio. Alexey has extensive background innovating and advancing to the clinic viral and non-viral gene therapies in several therapeutic areas including neurodegenerative, neuromuscular, hematologic, metabolic, and gastrointestinal disorders. Before joining Remedium, Alexey led high-priority R&D programs at organizations ranging from start-up to Fortune 500, such as Takeda, Biogen, Bioverativ, and Solid Biosciences.

Dr. Seregin holds PhD from The University of Texas Medical Branch at Galveston and is an inventor on a number of issued patents and patent applications covering the development of novel viral and non-viral vector technologies for a broad range of therapeutic indications. Dr. Seregin is a recognized authority in the field of genetic engineering and gene delivery, bringing over 15 years industrial and academic experience to Remedium, and having published in an extensive number of high-impact peer-reviewed journals.